Novartis clinical trial results sharingNovartis has long been dedicated to improving clinical trial data transparency, for an overview of our commitments please review:
Clinical trial results: Novartis recognizes the importance of informing the public about the results of its interventional clinical trials for innovative compounds, regardless of the outcome. We make the results of our clinical trials publicly available through peer-reviewed publications and posting of results on the Novartis clinical trial results database and other online public databases. Knowing the results of these trials enables both patients and their healthcare providers to make well-informed decisions regarding treatment risks and benefits.
To learn more about the results of Novartis-conducted trials, visit:
Sharing patient-level data: Novartis is also committed to sharing, with qualified external researchers, access to patient-level data and clinical study reports from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trials in line with applicable laws and regulations.
Novartis began in January 2014 to make available patient-level data with medicines and vaccines that have received a regulatory approval for a specified indication in the EU and U.S., under the provision that Novartis maintains the ability to publish the relevant clinical trial results in scientific journals. For more detailed information about patient-level data eligibility criteria and for external access requests please visit: